{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T22:53:29Z","timestamp":1648853609737},"reference-count":0,"publisher":"Hogrefe Publishing Group","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Therapeutische Umschau"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:p> Zusammenfassung. Myeloproliferative Neoplasien (MPN) sind h\u00e4matopoetische Stammzellerkrankungen, die als chronische Leuk\u00e4mien verlaufen. Driver-Mutationen in JAK2, Calretikulin (CALR) oder dem Thrombopoetin-Rezeptor MPL f\u00fchren \u00fcber eine Aktivierung des JAK2 Signaling zu einer \u00fcberm\u00e4ssigen Produktion reifer, myeloischer Blutzellen. Bei der Polyzyth\u00e4mia vera (PV) steht eine Polyglobulie im Vordergrund, bei der Essentiellen Thrombozyth\u00e4mie (ET) eine Thrombozytose und bei der Prim\u00e4ren Myelofibrose (PMF) eine Vermehrung der Megakaryozyten im Knochenmark mit zunehmender Knochenmarkfibrose. Die zunehmende molekulare Charakterisierung der MPN hat zu Fortschritten in der Diagnostik gef\u00fchrt und liefert wichtige prognostische Informationen. In der Therapie bieten JAK Inhibitoren und Interferone breitere therapeutische M\u00f6glichkeiten. Die allogene h\u00e4matopoetische Stammzelltransplantation bleibt vorerst die einzige, potentiell kurative Behandlungsoption und steht zunehmend auch \u00e4lteren Patienten offen. <\/jats:p>","DOI":"10.1024\/0040-5930\/a001128","type":"journal-article","created":{"date-parts":[[2020,4,28]],"date-time":"2020-04-28T19:29:48Z","timestamp":1588102188000},"page":"487-495","source":"Crossref","is-referenced-by-count":0,"title":["Myeloproliferative Neoplasien: Update zu Diagnostik und                Therapie"],"prefix":"10.1024","volume":"76","author":[{"given":"Sara C.","family":"Meyer","sequence":"first","affiliation":[{"name":"Departement Biomedizin, Universit\u00e4t Basel"},{"name":"Klinik f\u00fcr H\u00e4matologie, Universit\u00e4tsspital Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Drexler","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr H\u00e4matologie, Universit\u00e4tsspital Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Radek C.","family":"Skoda","sequence":"additional","affiliation":[{"name":"Departement Biomedizin, Universit\u00e4t Basel"},{"name":"Klinik f\u00fcr H\u00e4matologie, Universit\u00e4tsspital Basel"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"101","container-title":["Therapeutische Umschau"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/econtent.hogrefe.com\/doi\/pdf\/10.1024\/0040-5930\/a001128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,17]],"date-time":"2021-03-17T06:31:36Z","timestamp":1615962696000},"score":1,"resource":{"primary":{"URL":"https:\/\/econtent.hogrefe.com\/doi\/10.1024\/0040-5930\/a001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":0,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["10.1024\/0040-5930\/a001128"],"URL":"https:\/\/doi.org\/10.1024\/0040-5930\/a001128","relation":{},"ISSN":["0040-5930","1664-2864"],"issn-type":[{"value":"0040-5930","type":"print"},{"value":"1664-2864","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12]]}}}